Department of Neurology, Ohio State University Wexner Medical Center, Columbus (J.F.B.).
Department of Internal Medicine and Cognitive Health Services Research Program (J.B.S., R.A.H., A.T.G., R.W., E.M.B., D.A.L.), University of Michigan, Ann Arbor.
Circ Cardiovasc Qual Outcomes. 2024 Jun;17(6):e010288. doi: 10.1161/CIRCOUTCOMES.123.010288. Epub 2024 May 30.
The large and increasing number of adults living with dementia is a pressing societal priority, which may be partially mitigated through improved population-level blood pressure (BP) control. We explored how tighter population-level BP control affects the incidence of atherosclerotic cardiovascular disease (ASCVD) events and dementia.
Using an open-source ASCVD and dementia simulation analysis platform, the Michigan Chronic Disease Simulation Model, we evaluated how optimal implementation of 2 BP treatments based on the Eighth Joint National Committee recommendations and SPRINT (Systolic Blood Pressure Intervention Trial) protocol would influence population-level ASCVD events, global cognitive performance, and all-cause dementia. We simulated 3 populations (usual care, Eighth Joint National Committee based, SPRINT based) using nationally representative data to annually update risk factors and assign ASCVD events, global cognitive performance scores, and dementia, applying different BP treatments in each population. We tabulated total ASCVD events, global cognitive performance, all-cause dementia, optimal brain health, and years lived in each state per population.
Optimal implementation of SPRINT-based BP treatment strategy, compared with usual care, reduced ASCVD events in the United States by ≈77 000 per year and produced 0.4 more years of stroke- or myocardial infarction-free survival when averaged across all Americans. Population-level gains in years lived free of ASCVD events were greater for SPRINT-based than Eighth Joint National Committee-based treatment. Survival and years spent with optimal brain health improved with optimal SPRINT-based BP treatment implementation versus usual care: the average patient with hypertension lived 0.19 additional years and 0.3 additional years in optimal brain health. SPRINT-based BP treatment increased the number of years lived without dementia (by an average of 0.13 years/person with hypertension), but increased the total number of individuals with dementia, mainly through more adults surviving to advanced ages.
Tighter BP control likely benefits most individuals but is unlikely to reduce dementia prevalence and might even increase the number of older adults living with dementia.
大量且不断增加的痴呆症患者给社会带来了紧迫的压力,而通过改善人群血压(BP)控制可能会部分缓解这一问题。我们探讨了更严格的人群 BP 控制如何影响动脉粥样硬化性心血管疾病(ASCVD)事件和痴呆症的发病率。
我们使用开源的 ASCVD 和痴呆症模拟分析平台——密歇根慢性病模拟模型,评估了基于第八届联合国家委员会建议和 SPRINT(收缩压干预试验)方案的两种 BP 治疗方法的最佳实施如何影响人群 ASCVD 事件、整体认知表现和全因痴呆症。我们使用全国代表性数据模拟了 3 个人群(常规护理、第八届联合国家委员会方案、SPRINT 方案),每年更新风险因素并分配 ASCVD 事件、整体认知表现评分和痴呆症,在每个人群中应用不同的 BP 治疗方法。我们记录了每个人群的总 ASCVD 事件、整体认知表现、全因痴呆症、最佳脑健康和每种状态的生存时间。
与常规护理相比,SPRINT 方案的最佳 BP 治疗策略的实施每年可减少美国约 77000 例 ASCVD 事件,并使所有美国人的中风或心肌梗死无事件生存率平均增加 0.4 年。基于 SPRINT 的治疗方案在人群中获得的无 ASCVD 事件生存时间的增加大于基于第八届联合国家委员会的治疗方案。与常规护理相比,最佳 SPRINT 方案 BP 治疗的实施提高了生存和最佳脑健康的生存时间:平均高血压患者多存活 0.19 年,最佳脑健康多存活 0.3 年。SPRINT 方案的 BP 治疗增加了无痴呆症的生存时间(高血压患者平均增加 0.13 年/人),但增加了痴呆症患者的总数,主要是通过更多的成年人存活到高龄。
更严格的 BP 控制可能使大多数人受益,但不太可能降低痴呆症的患病率,甚至可能增加患有痴呆症的老年人数量。